Sintra

Migraine is a neurological condition causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to assess how well atogepant works in adults with migraine when used in everyday medical practice. Atogepant is an approved preventive treatment for migraines, and the study will include about 1000 adult participants prescribed this medication by their doctors worldwide. Participants will take atogepant tablets orally as prescribed by their healthcare providers following usual medical care. The study will observe participants over a two-year period without requiring extra treatments or procedures beyond their regular clinical visits. These visits will occur at hospitals or clinics according to each participant's routine care schedule. During the study, participants will attend regular check-ups where researchers will monitor their health and migraine symptoms. The main outcome measured will be the percentage of participants who report feeling "much better" or "very much better" by week 12, based on their own impression of change. There are no additional burdens expected for participants beyond their normal treatment and follow-up appointments.

Researchers are evaluating Exercogs4, a new digital program that combines augmented reality (AR) and gamification to provide tailored cognitive, physical, and social training aimed at preventing dementia in adults aged 55 and older who have modifiable risk factors. This randomized, controlled, assessor-blind trial involves 150 community-dwelling older adults and seeks to assess the feasibility, safety, and effectiveness of Exercogs4 in improving global cognitive function, physical performance, and social participation. Participants are randomly assigned to either the Exercogs4 intervention group or an active control group. Both groups complete supervised 60-minute sessions three times per week for 24 weeks. The Exercogs4 program includes interactive cognitive tasks (attention, memory, executive function), physical exercises (balance, gait, coordination), and social activities (cooperative and competitive) within a gamified AR environment that adjusts difficulty based on individual abilities. The control group follows a conventional multidomain program with the same frequency and duration but without AR or gamification. Assessments occur at baseline, 12 weeks, 24 weeks (end of intervention), and at 4 and 8 weeks post-intervention. Participants provide informed consent and undergo comprehensive baseline assessments. Outcome evaluations include cognitive testing (MoCA), physical performance (SPPB), social participation (WHODAS 2.0), usability, quality of life, safety monitoring, and risk factor changes. Session adherence and adverse events are recorded throughout, with adherence tracked via platform logs and therapist diaries. The study aims to offer evidence on the efficacy, usability, and scalability of Exercogs4 as a community-based dementia prevention tool for older adults.